Lancet
-
Randomized Controlled Trial Multicenter Study
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.
Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. ⋯ British Heart Foundation, the UK Marfan Trust, the UK Marfan Association.
-
More than 80% of public-access defibrillation attempts do not result in sustained return of spontaneous circulation in patients who have had an out-of-hospital cardiac arrest (OHCA) and a shockable heart rhythm before arrival of emergency medical service (EMS) personnel. Neurological and survival outcomes in such patients have not been evaluated. We aimed to assess the neurological status and survival outcomes in such patients. ⋯ None.